BioNTech stock surges 22% on Moderna cancer vaccine win. Why the gains could fade.

BioNTech, a former pioneer of mRNA cancer vaccines, was part of a broad rally Wednesday. Leerink analysts don’t expect the momentum to last.
Yahoo Finance

BioNTech sues Moderna for patent infringement over COVID shots

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices ...
Seeking Alpha

Moderna sued for violating patent linked to Pfizer/ BioNTech COVID-19 shot

Moderna (MRNA) faces a lawsuit in the U.S. for allegedly infringing patent rights related to the COVID-19 shot developed by Pfizer (PFE) and BioNTech (BNTX), marking the latest such case among COVID-19 vaccine makers. German vaccine maker BioNTech (BNTX ...
Blockonomi

BioNTech (BNTX) Stock Jumps 22% Following Moderna’s Cancer Vaccine Breakthrough

BioNTech (BNTX) stock rallied 22% after Moderna's cancer vaccine trial success, but analysts say the gains may be short-lived. Here's why.
Yahoo

Pfizer, BioNTech to pause COVID vaccine study due to low enrollment

Add Yahoo as a preferred source to see more of our stories on Google. Pfizer Inc. signage is seen on July 22, 2020 in New York City. Pfizer and partner BioNTech said they will halt a government-ordered post-marketing study for their COVID-19 vaccine ...
FT Markets

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces ...

Today’s actions expand on Arbutus and Genevant’s ongoing enforcement proceeding in the U.S. District Court for the District of New Jersey, seeking fair compensation for Pfizer/BioNTech’s infringement of five U.S. patents in the manufacture and sale of Pfizer/BioNTech’s mRNA-LNP COVID-19 vaccines.